Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Oct 12

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Oct 12

DOI: 10.23736/S1824-4785.20.03311-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Peptide and pseudo-peptide (PSMA) Cu-64 radiopharmaceuticals

Siroos MIRZAEI 1 , Rainer W. LIPP 2

1 Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria; 2 Department of Internal Medicine, Division of Oncology, Medical University of Graz, Austria


PDF


In recent years, the introduction of theranostic twins for specific diagnosis and treatment in patients with neuroendocrine tumors became a nuclear medicine success story. 64Cu/18F labeled prostate specific membrane antigen (PSMA) for molecular imaging with PET-CT and peptide radioligand therapy with 177Lu labeled PSMA inhibitors will favorably become the next theranostic twins in nuclear medicine history. 68Ga/ 64Cu/18F PSMA PET/CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity. In addition, it can be used to select patients for radioligand therapy and evaluate therapy response. 64Cu-labeled radiopharmaceuticals such as 64Cu-PSMA, and 64Cu-somatostatin analogs are promising imaging tools in the assessment of primary disease and also in the detection of disease recurrence and to evaluate therapy response. The long half-life of 64Cu allows the distribution of the tracer to PET centers as a satellite concept, who otherwise has no access to 68Ga generators.


KEY WORDS: PET-CT; 64Cu-DOTA-TOC; 64Cu-PSMA

top of page